Valserhône, France

Martine Malissard

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Pierre Fabre Medicament. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Martine Malissard: Innovator in Cancer Treatment

Introduction

Martine Malissard is a notable inventor based in Valserhône, France. She has made significant contributions to the field of cancer treatment through her innovative work on immunocytokines. Her research focuses on developing new therapeutic options for patients battling cancer.

Latest Patents

Martine Malissard holds 1 patent for her invention titled "Immunocytokines for the treatment of cancer." This patent describes novel immunocytokines that are designed to treat cancer effectively. The fusion proteins involved in this invention consist of an antibody or an antigen-binding fragment fused to a cleavable peptide linker, along with a cytokine or its functional fragments. The patent also outlines methods of treatment utilizing these immunocytokines.

Career Highlights

Martine Malissard is currently associated with Pierre Fabre Medicament, a prominent company in the pharmaceutical industry. Her work at this organization has allowed her to focus on groundbreaking research aimed at improving cancer therapies.

Collaborations

Throughout her career, Martine has collaborated with esteemed colleagues, including Jean-François Haeuw and Barbara Akla. These partnerships have contributed to the advancement of her research and the development of innovative treatment options.

Conclusion

Martine Malissard's contributions to cancer treatment through her patented immunocytokines highlight her role as a leading inventor in the field. Her work continues to inspire advancements in medical research and therapy.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…